Nebilet 5 mg 14 tablets

Tradename

Nebilet

Nebilet

Composition

Each tablet contains:

Nebivolol 5 mg

Auxiliary components:

Polysorbate 80, hypromellose, lactose monohydrate, starch, croscarmellose sodium, microcrystalline cellulose, silicon, magnesium stearate.

Properties

III generation cardioselective beta1-blocker with vasodilating properties. The active substance is a racemate consisting of two enantiomers: D-nebivolol and L-nebivolol. D-nebivolol is a competitive and highly selective β1-adrenergic receptor blocker; L-nebivolol has a mild vasodilator effect by modulating the release of vasodilating factor (NO) from the vascular endothelium.

Nebivolol lowers heart rate and blood pressure at rest and during exertion, reduces left ventricular end-diastolic pressure, decreases systemic vascular resistance, improves diastolic heart function (decreases filling pressure), increases ejection fraction; causes an antianginal effect in patients with coronary artery disease.

The antihypertensive effect is also due to a decrease in the activity of the renin-angiotensin system (does not directly correlate with a change in renin activity in the blood plasma).

Indications

Arterial hypertension.

Stable chronic heart failure of mild to moderate severity (as part of combination therapy) in patients over 70 years old.

Method of administration and dosage:

Contraindications

Hypersensitivity to nebivolol; acute heart failure; chronic heart failure in the stage of decompensation (requiring intravenous administration of drugs with a positive inotropic effect); severe arterial hypotension (systolic blood pressure less than 90 mm Hg); SSSU, including sinoatrial blockade; AV block II and III degree (without an artificial pacemaker); bradycardia (heart rate less than 60 beats / min); cardiogenic shock; pheochromocytoma (without the simultaneous use of alpha-blockers); metabolic acidosis; severe liver dysfunction; severe renal dysfunction (CC less than 20 ml / min); history of bronchospasm and bronchial asthma; severe obliterating peripheral vascular disease (intermittent claudication, Raynaud’s syndrome); myasthenia gravis; depression; simultaneous use with floktaphenin, sultopride; period of breastfeeding; children and adolescents up to 18 years old.

Precautionary measures:

It is unacceptable to abruptly stop taking beta-blockers (with abrupt cessation of treatment, the «withdrawal» syndrome may develop), treatment, if possible, should be stopped gradually.

Side effects

From the nervous system: very often — dizziness; often — headache, dizziness, weakness, paresthesia; very rarely — fainting.

From the side of the cardiovascular system: very often — bradycardia; often — aggravation of the course of chronic heart failure, AV-blockade of the I degree, orthostatic hypotension.

From the respiratory system: often — shortness of breath; infrequently — bronchospasm (including in the absence of a history of obstructive pulmonary disease).